an animation of body cells floating around

Targeted
radio frequency
based treatment
for solid tumors

The first AI radio frequency system for making Cancer History

ONCOWAVE RF develops a breakthrough technology of personalized medicine, using a unique artificial intelligence (AI) based system for modeling cancer cell biophysics.

Personalized Solid Tumor Targeting

The company develops a unique medical system based on the morphological properties of cancer cells of a specific individual.

The system takes advantage of a model of the cancer cell which is based on an AI simulation.

Its unique technology is based on introducing a coded 2.4 GHz radio wave to the whole body for stimulating the immune system and eliminating cancer cells.

The system can be used in any clinic in an outpatient setup or in the patient's house.

The Need

About half of cancer patients will eventually succumb to disease. This population includes incurable primary tumors or those with metastatic disease, which failed 1st and 2nd lines of treatment. Almost all of these patients will succumb to disease within 3-6 months.

The available modalities for these patients include chemotherapy which has minimal benefit and significant morbidity.

Our technology is unique in its ability to target only the cancer cells and not normal tissue. It has no side effects since it is directed to target only the specific type of cancer cells of an individual patient.

It is approved for clinical trials by the Israeli regulatory agencies and is safe for the patients, the medical staff and care givers. As such it can be applied in any clinic or in the house of the patient.

Market

The initial market segment will be in the field of oncology, due to the relatively ease of regulation and huge market potential.

The next goal would be to increase treatment eligibility to 2nd modality and even 1st modality along with immunotherapy, for treatment of specific populations with malignant tumors for which the standard of care offers minimal outcome.

Following goals would include, penetrating other very large market of patients including pediatric patients, benign tumors and those with non-solid tumors (leukemia and lymphoma).

USP & Benefits

Several studies are trying to develop similar products, but ours is the first to offer personalized medicine approach which is approved for clinical study.